首页> 外文OA文献 >A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

【2h】

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

机译：在难治性固体肿瘤患者中，Solitomab（MT110，AMG 110），双特异性EPCAM / CD3 T细胞（BITE®）抗体构建体的多中心阶段1研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Maxim Kebenko; Marie-Elisabeth Goebeler; Martin Wolf; Annette Hasenburg; Ruth Seggewiss-Bernhardt; Barbara Ritter; Beate Rautenberg; Djordje Atanackovic; Andrea Kratzer; James B. Rottman; Matthias Friedrich; Eva Vieser; Stefanie Elm; Ingrid Patzak; Dorothea Wessiepe; Sabine Stienen; Walter Fiedler;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE~?) antibody construct, in patients with refractory solid tumors [J] . Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, Oncoimmunology. . 2018,第8期

机译：在难治性固体肿瘤患者中，Solitomab（MT110，AMG 110），双特异性EPCAM / CD3 T细胞（咬合〜β）抗体构建体的多中心阶段1研究
2. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) [J] . Ravandi Farhad, Stein Anthony S., Kantarjian Hagop M., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：AMG 330的第1阶段第一人体研究，抗CD33双特异性T细胞参录手（咬合（R））抗体构建体，复发/难治性急性髓性白血病（R / R AML）
3. Treatment with AMG 420, an Anti-B-Cell Maturation Antigen (BCMA) Bispecific T-Cell Engager (BiTE (R)) Antibody Construct, Induces Minimal Residual Disease (MRD) Negative Complete Responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) Patients: Results of a First-in-Human (FIH) Phase I Dose Escalation Study [J] . Topp Max S., Duell Johannes, Zugmaier Gerhard, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用AMG 420处理，一种抗B细胞成熟抗原（BCMA）双特异性T细胞参录手（咬合（R））抗体构建体，诱导最小的残留疾病（MRD）在复发和/或难治度（R / R））多发性骨髓瘤（mm）患者：先进（FIH）I剂量升级研究的结果
4. Comparative pharmacology of the human CD19/CD3 Bispecific T-cell engager (BiTERTM) antibody blinatumomab with the hybrid murine surrogate CD19/CD3 BiTE antibody hyS103. [D] . Fuhrmann, Stacy R. 2010

机译：人CD19 / CD3双特异性T细胞衔接子（BiTERTM）抗体blinatumomab与杂种鼠替代CD19 / CD3 BiTE抗体hyS103的比较药理学。
5. A multicenter phase 1 study of solitomab (MT110 AMG 110) a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct in patients with refractory solid tumors [O] . Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, 2018

机译：索利妥单抗（MT110AMG 110）是双特异性EpCAM / CD3 T细胞衔接子（BiTE®）抗体构建物的多中心1期研究用于难治性实体瘤患者
6. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110 [O] . Petsch, Silke, Gires, Olivier, Rüttinger, Dominik, 2011

机译：在癌症患者血清中发现的EpCAM胞外域浓度不会显着影响EpCAM / CD3-双特异性BiTE抗体MT110的重定向裂解和T细胞活化

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

著录项

引文网络

相似文献

相关主题

期刊订阅